Kite Pharma (NASDAQ: KITE) recently received a number of ratings updates from brokerages and research firms:

  • 9/19/2016 – Kite Pharma had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $72.00 price target on the stock.
  • 9/13/2016 – Kite Pharma was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $63.91 price target on the stock.
  • 9/7/2016 – Kite Pharma was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $63.91 price target on the stock.
  • 9/6/2016 – Kite Pharma was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $62.43 price target on the stock.
  • 8/30/2016 – Kite Pharma was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $62.43 price target on the stock.
  • 8/30/2016 – Kite Pharma is now covered by analysts at BTIG Research. They set a “neutral” rating on the stock.
  • 8/24/2016 – Kite Pharma was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $57.97 price target on the stock.
  • 8/15/2016 – Kite Pharma was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $57.97 price target on the stock.
  • 8/9/2016 – Kite Pharma had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $77.00 price target on the stock, down previously from $87.00.
  • 8/9/2016 – Kite Pharma was given a new $60.00 price target on by analysts at Barclays PLC. They now have a “hold” rating on the stock.
  • 8/9/2016 – Kite Pharma was given a new $80.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 8/5/2016 – Kite Pharma had its “buy” rating reaffirmed by analysts at Jefferies Group.
  • 8/2/2016 – Kite Pharma was upgraded by analysts at Vetr from a “sell” rating to a “buy” rating. They now have a $58.58 price target on the stock.
  • 8/1/2016 – Kite Pharma was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $53.26 price target on the stock.
  • 7/26/2016 – Kite Pharma was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $53.26 price target on the stock.
  • 7/26/2016 – Kite Pharma had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $75.00 price target on the stock.
  • 7/22/2016 – Kite Pharma had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $80.00 price target on the stock.

Kite Pharma Inc. (NASDAQ:KITE) traded down 0.71% during mid-day trading on Tuesday, reaching $55.61. 377,330 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $58.62 and a 200-day moving average of $51.41. The stock’s market cap is $2.76 billion. Kite Pharma Inc. has a one year low of $38.41 and a one year high of $89.84.

Kite Pharma (NASDAQ:KITE) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.21) by $0.30. The business earned $4.80 million during the quarter, compared to analyst estimates of $4.86 million. Kite Pharma had a negative return on equity of 32.91% and a negative net margin of 873.86%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.26) EPS. On average, equities research analysts anticipate that Kite Pharma Inc. will post ($5.82) earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/analysts-weekly-ratings-changes-for-kite-pharma-kite.html

In other Kite Pharma news, SVP Jeffrey Wiezorek sold 1,500 shares of Kite Pharma stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $50.00, for a total transaction of $75,000.00. Following the completion of the transaction, the senior vice president now owns 16,367 shares of the company’s stock, valued at approximately $818,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Helen Susan Kim sold 35,900 shares of Kite Pharma stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $60.27, for a total value of $2,163,693.00. Following the transaction, the executive vice president now directly owns 42,500 shares of the company’s stock, valued at approximately $2,561,475. The disclosure for this sale can be found here. Company insiders own 20.60% of the company’s stock.

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

5 Day Chart for NASDAQ:KITE

Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.